drugset / Trial / NCT06151652

Effect of Alpha-Lipoic Acid Supplementation on the Incidence of Postoperative Atrial Fibrillation in Cardiac Surgery Patients

NCT06151652

Phase 4 Unknown 350 enrolled Ain Shams University
RandomizedParallel-groupDouble-blindPrevention

Summary

ALA is administered orally since it is without difficulty absorbed in the stomach. ALA goes through the blood brain barrier and does not show toxic effects and actions at doses used for prophylactic and therapeutic purposes. This has encouraged us to use an efficient anti-oxidant and anti-inflammatory agent, alpha-lipoic acid (biochemical) as a relevant option to prevent POAF.

Timeline

Start
2023-01-01
Primary completion
2024-03-01
Completion
2024-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator alpha-lipoic acid Small molecule 600 mg Oral

Indications